ROIV Fundamental Analysis - ROIVANT SCIENCES LTD

Name: ROIVANT SCIENCES LTD (ROIV) Stock
Brand: ROIVANT SCIENCES LTD
Rating: 7 (3 reviews)

Fundamental Rating

Taking everything into account, ROIV scores 4 out of 10 in our fundamental rating. ROIV was compared to 534 industry peers in the Biotechnology industry. ROIV has a great financial health rating, but its profitability evaluates not so good. ROIV is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ROIV had negative earnings in the past year.

In the past year ROIV has reported a negative cash flow from operations.

In the past 5 years ROIV reported 4 times negative net income.

In the past 5 years ROIV always reported negative operating cash flow.

1.2 Ratios

ROIV's Return On Assets of -9.75% is amongst the best of the industry. ROIV outperforms 84.08% of its industry peers.

The Return On Equity of ROIV (-11.29%) is better than 87.45% of its industry peers.

		Industry Rank	Sector Rank
ROA	-9.75%
ROE	-11.29%
ROIC	N/A

ROA(3y)4.94%

ROA(5y)-9.82%

ROE(3y)-5.99%

ROE(5y)-22.8%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ROIV has a Gross Margin of 96.33%. This is amongst the best in the industry. ROIV outperforms 95.69% of its industry peers.

ROIV's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for ROIV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	96.33%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.96%

GM growth 5Y-0.3%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ROIV has been reduced compared to 1 year ago.

ROIV has more shares outstanding than it did 5 years ago.

ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 12.48 indicates that ROIV is not in any danger for bankruptcy at the moment.

The Altman-Z score of ROIV (12.48) is better than 86.14% of its industry peers.

ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	12.48

ROIC/WACCN/A

WACC9.22%

2.3 Liquidity

ROIV has a Current Ratio of 40.54. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.

ROIV has a better Current ratio (40.54) than 99.06% of its industry peers.

ROIV has a Quick Ratio of 40.54. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.

ROIV has a Quick ratio of 40.54. This is amongst the best in the industry. ROIV outperforms 99.06% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	40.54
Quick Ratio	40.54

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ROIV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.09%, which is quite good.

The Revenue for ROIV has decreased by -79.10% in the past year. This is quite bad

ROIV shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.56% yearly.

EPS 1Y (TTM)9.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-375%

Revenue 1Y (TTM)-79.1%

Revenue growth 3Y-19.3%

Revenue growth 5Y-15.56%

Sales Q2Q%-96.06%

3.2 Future

The Earnings Per Share is expected to grow by 52.18% on average over the next years. This is a very strong growth

Based on estimates for the next years, ROIV will show a very strong growth in Revenue. The Revenue will grow by 104.98% on average per year.

EPS Next Y-481.69%

EPS Next 2Y-143.35%

EPS Next 3Y-53.93%

EPS Next 5Y52.18%

Revenue Next Year-75.49%

Revenue Next 2Y1.51%

Revenue Next 3Y111.12%

Revenue Next 5Y104.99%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ROIV. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ROIV. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ROIV's earnings are expected to decrease with -53.93% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-143.35%

EPS Next 3Y-53.93%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ROIV does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ROIVANT SCIENCES LTD

NASDAQ:ROIV (11/7/2025, 4:10:43 PM)

After market: 20.62 0 (0%)

20.62

+0.05 (+0.24%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-11 2025-08-11/bmo

Earnings (Next)N/A N/A

Inst Owners65.29%

Inst Owner ChangeN/A

Ins Owners3.93%

Ins Owner Change5.18%

Market Cap14.08B

Revenue(TTM)23.23M

Net Income(TTM)-490.63M

Analysts85.56

Price Target20.04 (-2.81%)

Short Float %5.93%

Short Ratio3.29

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)1.66%

Min EPS beat(2)-4.36%

Max EPS beat(2)7.69%

EPS beat(4)2

Avg EPS beat(4)41.21%

Min EPS beat(4)-18.6%

Max EPS beat(4)180.12%

EPS beat(8)5

Avg EPS beat(8)41.21%

EPS beat(12)7

Avg EPS beat(12)27.24%

EPS beat(16)8

Avg EPS beat(16)12.33%

Revenue beat(2)0

Avg Revenue beat(2)-78.43%

Min Revenue beat(2)-86.28%

Max Revenue beat(2)-70.59%

Revenue beat(4)0

Avg Revenue beat(4)-67.8%

Min Revenue beat(4)-91.09%

Max Revenue beat(4)-23.24%

Revenue beat(8)3

Avg Revenue beat(8)-20.11%

Revenue beat(12)6

Avg Revenue beat(12)-3.85%

Revenue beat(16)8

Avg Revenue beat(16)10.78%

PT rev (1m)2.82%

PT rev (3m)1.42%

EPS NQ rev (1m)-1.01%

EPS NQ rev (3m)-9.02%

EPS NY rev (1m)-0.81%

EPS NY rev (3m)-10.52%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-25.15%

Revenue NY rev (1m)1.76%

Revenue NY rev (3m)-21.4%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	606.08
P/FCF	N/A
P/OCF	N/A
P/B	3.24
P/tB	3.24
EV/EBITDA	N/A

EPS(TTM)-0.7

EYN/A

EPS(NY)-1.48

Fwd EYN/A

FCF(TTM)-1.26

FCFYN/A

OCF(TTM)-1.25

OCFYN/A

SpS0.03

BVpS6.36

TBVpS6.36

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-9.75%
ROE	-11.29%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	96.33%
FCFM	N/A

ROA(3y)4.94%

ROA(5y)-9.82%

ROE(3y)-5.99%

ROE(5y)-22.8%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.96%

GM growth 5Y-0.3%

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	74.56%
Cap/Sales	33.01%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	40.54
Quick Ratio	40.54
Altman-Z	12.48

F-Score4

WACC9.22%

ROIC/WACCN/A

Cap/Depr(3y)35.38%

Cap/Depr(5y)N/A

Cap/Sales(3y)13.59%

Cap/Sales(5y)19.32%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)9.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-375%

EPS Next Y-481.69%

EPS Next 2Y-143.35%

EPS Next 3Y-53.93%

EPS Next 5Y52.18%

Revenue 1Y (TTM)-79.1%

Revenue growth 3Y-19.3%

Revenue growth 5Y-15.56%

Sales Q2Q%-96.06%

Revenue Next Year-75.49%

Revenue Next 2Y1.51%

Revenue Next 3Y111.12%

Revenue Next 5Y104.99%

EBIT growth 1Y-13.75%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-15.98%

EBIT Next 3Y-3.57%

EBIT Next 5YN/A

FCF growth 1Y-1.4%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-1.17%

OCF growth 3YN/A

OCF growth 5YN/A

ROIVANT SCIENCES LTD / ROIV FAQ

What is the ChartMill fundamental rating of ROIVANT SCIENCES LTD (ROIV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ROIV.

What is the valuation status of ROIVANT SCIENCES LTD (ROIV) stock?

ChartMill assigns a valuation rating of 0 / 10 to ROIVANT SCIENCES LTD (ROIV). This can be considered as Overvalued.

How profitable is ROIVANT SCIENCES LTD (ROIV) stock?

ROIVANT SCIENCES LTD (ROIV) has a profitability rating of 3 / 10.

What is the expected EPS growth for ROIVANT SCIENCES LTD (ROIV) stock?

The Earnings per Share (EPS) of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -481.69% in the next year.

ROIVANT SCIENCES LTD (ROIV) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ROIVANT SCIENCES LTD / ROIV FAQ

What is the ChartMill fundamental rating of ROIVANT SCIENCES LTD (ROIV) stock?

What is the valuation status of ROIVANT SCIENCES LTD (ROIV) stock?

How profitable is ROIVANT SCIENCES LTD (ROIV) stock?

What is the expected EPS growth for ROIVANT SCIENCES LTD (ROIV) stock?